A few thoughts…
Last night, Trump “endorsed” 2 drugs in the therapeutics arena. Trump didn’t actually “approve” their EUAs, but rather was implying that he “approves of” their EUAs. He was saying… based on his personal experience with the drugs, he supports the submittal of the EUAs to the FDA. The FDA is the agency that actually does the approval.
So now… Eli and Regeneron are in the “EUA-Queue” with us. And the good news is… Trump will push for therapeutic EUAs to be approved ASAP!
What??? You didn’t expect to have any competition??? That’s ok…
Just don’t forget who we are:
• We own the patent to RLF100 and the process for synthesizing it.
• We demonstrate the best results out of all covid drugs I’ve seen.
• We block the virus from attaching to host cells in the lungs, AND… we prevent the cytokine storm AND... reduce inflammation!
• We are already determined safe by the FDA.
• Our intravenous RLF100 was submitted for EUA on 9/17 – awaiting FDA approval.
• Our RLF100 clinical trials have reached the interim 102 patients on 9/30 – awaiting results.
• Our clinical trial for the RLF100 treatment inhaler has been designed, submitted, and is expected to finish this year.
• Our clinical trial for the RLF100 PREVENTATIVE inhaler has been designed, submitted, and is expected to finish next year.
• We show promise for other lung applications beyond Covid, which also need to be studied and tested separately.
• We signed a Cooperative Agreement with NIH’s Institute of Arthritis and Infectious Diseases to test RLF-100 against the flu virus and other viruses that attack the lungs.
• We signed a contract with Bachem Americas to manufacture drug substance for 1 million patients.
• We signed a contract with Nephron Pharma to manufacture enough RLF100 for 1 million patients.
• We signed a contract with the largest supplier of inhaled sterile drugs in the United States to supply RLF-100 to any US hospital overnight.
• We obtained Companionate Care Protocol in Israel and we’re in the process of determining how to service it.
• NeuroRX’s CEO Dr. Javitt is ranked among the top 1% of quoted scientists worldwide, has successfully taken 7 drugs through the FDA process, and has served in key leadership roles under presidents Clinton, Bush Jr, Bush Sr, and Reagan.
• NeuroRX’s Chief of Operations, Robert Bestoff spent his career at Lilly & Pfizer. At Pfizer, he was head of the entire neuro science and pain division, responsible for $10B of their drugs.
• NeuroRX’s Manufacturing Coordinator, Rich Siegel, is the former head of Johnson & Johnson’s drug portfolio.
• Relief just appointed industry veteran Jack Weinstein as CFO, AND retained previous CFO Jeremy Meinen as Principle Finance and Accounting Officer.
• Doctor (and Congressman) Andy Harris is 1 of 3 experts on the Data Monitoring Committee.
Our team is top-notch. Our team is focused. We're making steady, precision progress. When it’s “go time”… the world will know!
(These are my opinions. I am not a professional. I take risky positions. Please do your own due diligence and evaluation, and seek professional guidance before trading or investing.)
Disclaimer: I am not a professional advisor. Seek professional advice before investing or trading. I take risky positions and do not advise anyone to follow my opinions or actions.
